We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion recommending approval of its BTK inhibitor, Jaypirca (pirtobrutinib), for treating relapsed or refractory chronic lymphocytic leukemia (CLL) in patients who have been previously treated with a BTK inhibitor in the European Union. The approval was based on data from the phase III BRUIN CLL-321 study.
The European Commission is expected to give its decision in a couple of months. Jaypirca is already approved in the EU on a conditional basis for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a BTK inhibitor.
Lilly’s shares have risen 16.2% in the past year against a decline of 0.9% for the industry.
Image Source: Zacks Investment Research
LLY’s Jaypirca Sales Performance in 2024
Jaypirca was approved in the United States for treating CLL or small lymphocytic lymphoma in patients who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor in December 2023. It was approved for the MCL indication in the United States in January 2023.
Jaypirca is one of Lilly’s several new drugs that have contributed to top-line growth in 2024. It recorded $337.0 million in sales in 2024. The drug is also being studied in earlier lines of therapy to enable broader use for the approved indications of CLL and MCL.
What BTK Inhibitors are Available Currently?
Some BTK inhibitors available in the market for CLL are AbbVie (ABBV - Free Report) and J&J’s (JNJ - Free Report) Imbruvica, AstraZeneca’s (AZN - Free Report) Calquence or BeiGene’s Brukinsa. In the last few quarters, sales of AbbVie/JNJ’s Imbruvica have been declining steadily amid rising competition from Brukinsa and AstraZeneca’s Calquence, all of which are approved by the FDA to treat similar indications. None of these drugs are approved for relapsed or refractory CLL in the post-BTK inhibitor setting.
Image: Bigstock
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
Eli Lilly and Company (LLY - Free Report) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion recommending approval of its BTK inhibitor, Jaypirca (pirtobrutinib), for treating relapsed or refractory chronic lymphocytic leukemia (CLL) in patients who have been previously treated with a BTK inhibitor in the European Union. The approval was based on data from the phase III BRUIN CLL-321 study.
The European Commission is expected to give its decision in a couple of months. Jaypirca is already approved in the EU on a conditional basis for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a BTK inhibitor.
Lilly’s shares have risen 16.2% in the past year against a decline of 0.9% for the industry.
Image Source: Zacks Investment Research
LLY’s Jaypirca Sales Performance in 2024
Jaypirca was approved in the United States for treating CLL or small lymphocytic lymphoma in patients who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor in December 2023. It was approved for the MCL indication in the United States in January 2023.
Jaypirca is one of Lilly’s several new drugs that have contributed to top-line growth in 2024. It recorded $337.0 million in sales in 2024. The drug is also being studied in earlier lines of therapy to enable broader use for the approved indications of CLL and MCL.
What BTK Inhibitors are Available Currently?
Some BTK inhibitors available in the market for CLL are AbbVie (ABBV - Free Report) and J&J’s (JNJ - Free Report) Imbruvica, AstraZeneca’s (AZN - Free Report) Calquence or BeiGene’s Brukinsa. In the last few quarters, sales of AbbVie/JNJ’s Imbruvica have been declining steadily amid rising competition from Brukinsa and AstraZeneca’s Calquence, all of which are approved by the FDA to treat similar indications. None of these drugs are approved for relapsed or refractory CLL in the post-BTK inhibitor setting.
LLY’s Zacks Rank
Eli Lilly currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Eli Lilly and Company Price and Consensus
Eli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote